Lawsone

Identification

Name
Lawsone
Accession Number
DB04744
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Similar Structures
Synonyms
  • 2-hydroxy-1,4-naphthalenedione
  • 2-hydroxy-1,4-naphthoquinone
  • 2-Hydroxynaphthoquinone
External IDs
NSC-27285 / NSC-52500 / NSC-8625
Categories
UNII
TLH4A6LV1W
CAS number
83-72-7
Weight
Average: 174.1528
Monoisotopic: 174.031694058
Chemical Formula
C10H6O3
InChI Key
CSFWPUWCSPOLJW-UHFFFAOYSA-N
InChI
InChI=1S/C10H6O3/c11-8-5-9(12)10(13)7-4-2-1-3-6(7)8/h1-5,12H
IUPAC Name
2-hydroxy-1,4-dihydronaphthalene-1,4-dione
SMILES
OC1=CC(=O)C2=CC=CC=C2C1=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with 2-HYDROXY-1,4-NAPHTHOQUINONE.
AmrinoneThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Amrinone.
AzimilideThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Azimilide.
BuspironeThe metabolism of Buspirone can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.
BusulfanThe serum concentration of Busulfan can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.
DidanosineDidanosine can cause a decrease in the absorption of 2-HYDROXY-1,4-NAPHTHOQUINONE resulting in a reduced serum concentration and potentially a decrease in efficacy.
DocetaxelThe metabolism of Docetaxel can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.
EtravirineThe serum concentration of Etravirine can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.
FosphenytoinThe serum concentration of 2-HYDROXY-1,4-NAPHTHOQUINONE can be decreased when it is combined with Fosphenytoin.
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C10368
PubChem Compound
6755
PubChem Substance
46509125
ChemSpider
10430995
BindingDB
50049066
ChEBI
44401
ChEMBL
CHEMBL240963
HET
NQ
Wikipedia
Lawsone
PDB Entries
2d0e

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.8 mg/mLALOGPS
logP0.99ALOGPS
logP0.98ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)8.02ChemAxon
pKa (Strongest Basic)-4.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity48.15 m3·mol-1ChemAxon
Polarizability16.42 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8282
Caco-2 permeable+0.7343
P-glycoprotein substrateNon-substrate0.5873
P-glycoprotein inhibitor IInhibitor0.5
P-glycoprotein inhibitor IINon-inhibitor0.8995
Renal organic cation transporterNon-inhibitor0.8735
CYP450 2C9 substrateNon-substrate0.7873
CYP450 2D6 substrateNon-substrate0.9245
CYP450 3A4 substrateNon-substrate0.6861
CYP450 1A2 substrateInhibitor0.9206
CYP450 2C9 inhibitorInhibitor0.7177
CYP450 2D6 inhibitorNon-inhibitor0.8078
CYP450 2C19 inhibitorNon-inhibitor0.7624
CYP450 3A4 inhibitorNon-inhibitor0.9078
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5311
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.9077
BiodegradationNot ready biodegradable0.8819
Rat acute toxicity3.0215 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9541
hERG inhibition (predictor II)Non-inhibitor0.931
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as naphthoquinones. These are compounds containing a naphthohydroquinone moiety, which consists of a benzene ring linearly fused to a bezene-1,4-dione (quinone).
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Naphthoquinones
Direct Parent
Naphthoquinones
Alternative Parents
Quinones / Aryl ketones / Vinylogous acids / Enols / Organic oxides / Hydrocarbon derivatives
Substituents
Naphthoquinone / Aryl ketone / Quinone / Vinylogous acid / Ketone / Enol / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organooxygen compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
naphthoquinone (CHEBI:44401) / alpha-Naphthoquinones (C10368)

Drug created on September 11, 2007 11:49 / Updated on August 08, 2018 12:08